Thoracic Cancer最新文献_第5页

A bone tumor-like chest wall mass lesion with pathological rib fractures observed 13 years after lung stereotactic body radiotherapy: A case report. 肺立体定向体放射治疗 13 年后观察到的伴有病理性肋骨骨折的骨肿瘤样胸壁肿块病变：病例报告。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-07 DOI: 10.1111/1759-7714.15419

Masaki Matsuda, Jiro Ichikawa, Takafumi Komiyama, Kojiro Onohara, Masahide Saito, Hikaru Nemoto, Mizuki Kubota, Hiroshi Onishi

引用次数: 0

Computed tomography-based radiomics and clinical-genetic features for brain metastasis prediction in patients with stage III/IV epidermal growth factor receptor-mutant non-small-cell lung cancer. 基于计算机断层扫描的放射组学和临床遗传学特征预测 III/IV 期表皮生长因子受体突变非小细胞肺癌患者的脑转移。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-05 DOI: 10.1111/1759-7714.15410

Mei Zheng, Xiaorong Sun, Haoran Qi, Mingzhu Zhang, Ligang Xing

{"title":"Computed tomography-based radiomics and clinical-genetic features for brain metastasis prediction in patients with stage III/IV epidermal growth factor receptor-mutant non-small-cell lung cancer.","authors":"Mei Zheng, Xiaorong Sun, Haoran Qi, Mingzhu Zhang, Ligang Xing","doi":"10.1111/1759-7714.15410","DOIUrl":"https://doi.org/10.1111/1759-7714.15410","url":null,"abstract":"Purpose: To evaluate the value of computed tomography (CT)-based radiomics combined with clinical-genetic features in predicting brain metastasis in patients with stage III/IV epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC).Methods: The study included 147 eligible patients treated at our institution between January 2018 and May 2021. Patients were randomly divided into two cohorts for model training (n = 102) and validation (n = 45). Radiomics features were extracted from the chest CT images before treatment, and a radiomics signature was constructed using the Least Absolute Shrinkage and Selection Operator regression. Kaplan-Meier survival analysis was used to describe the differences in brain metastasis-free survival (BM-FS) risk. A clinical-genetic model was developed using Cox regression analysis. Radiomics, genetic, and combined prediction models were constructed, and their predictive performances were evaluated by the concordance index (C-index).Results: Patients with a low radiomics score had significantly longer BM-FS than those with a high radiomics score in both the training (p < 0.0001) and the validation (p = 0.0016) cohorts. The C-indices of the nomogram, which combined the radiomics signature and N stage, overall stage, third-generation tyrosine kinase inhibitor treatment, and EGFR mutation status, were 0.886 (95% confidence interval [CI] 0.823-0.949) and 0.811 (95% CI 0.719-0.903) in the training and validation cohorts, respectively. The combined model achieved a higher discrimination and clinical utility than the single prediction models.Conclusions: The combined radiomics-genetic model could be used to predict BM-FS in stage III/IV NSCLC patients with EGFR mutations.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer. 根据非小细胞肺癌肝转移的生物标志物构建提名图模型

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-04 DOI: 10.1111/1759-7714.15417

Tian Zhang, Yajuan Zhang, Yunfeng Ni, Xiaohui Jia, Yanlin Li, Ziyang Mao, Panpan Jiang, Xiaolan Fu, Min Jiao, Lili Jiang, Wenjuan Wang, Hui Guo, Ying Zan, Mengjie Liu

{"title":"Construction of a nomogram model based on biomarkers for liver metastasis in non-small cell lung cancer.","authors":"Tian Zhang, Yajuan Zhang, Yunfeng Ni, Xiaohui Jia, Yanlin Li, Ziyang Mao, Panpan Jiang, Xiaolan Fu, Min Jiao, Lili Jiang, Wenjuan Wang, Hui Guo, Ying Zan, Mengjie Liu","doi":"10.1111/1759-7714.15417","DOIUrl":"https://doi.org/10.1111/1759-7714.15417","url":null,"abstract":"Background: Patients with non-small cell lung cancer (NSCLC) with liver metastasis have a poor prognosis, and there are no reliable biomarkers for predicting disease progression. Currently, no recognized and reliable prediction model exists to anticipate liver metastasis in NSCLC, nor have the risk factors influencing its onset time been thoroughly explored.Methods: This study conducted a retrospective analysis of 434 NSCLC patients from two hospitals to assess the association between the risk and timing of liver metastasis, as well as several variables.Results: The patients were divided into two groups: those without liver metastasis and those with liver metastasis. We constructed a nomogram model for predicting liver metastasis in NSCLC, incorporating elements such as T stage, N stage, M stage, lack of past radical lung cancer surgery, and programmed death ligand 1 (PD-L1) levels. Furthermore, NSCLC patients with wild-type EGFR, no prior therapy with tyrosine kinase inhibitors (TKIs), and no prior radical lung cancer surgery showed an elevated risk of early liver metastasis.Conclusion: In conclusion, the nomogram model developed in this study has the potential to become a simple, intuitive, and customizable clinical tool for assessing the risk of liver metastasis in NSCLC patients following validation. Furthermore, it provides a framework for investigating the timing of metachronous liver metastasis.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CBX4/miR-190 regulatory loop inhibits lung cancer metastasis. CBX4/miR-190调节环抑制肺癌转移

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-04 DOI: 10.1111/1759-7714.15415

Jian Wang, Xiang Zhu, Yue Yu, Jie Ge, Wei Chen, Wengui Xu, Wen Zhou

{"title":"CBX4/miR-190 regulatory loop inhibits lung cancer metastasis.","authors":"Jian Wang, Xiang Zhu, Yue Yu, Jie Ge, Wei Chen, Wengui Xu, Wen Zhou","doi":"10.1111/1759-7714.15415","DOIUrl":"https://doi.org/10.1111/1759-7714.15415","url":null,"abstract":"Background: Lung cancer is one of the major threats to human life worldwide. MiR-190 has been found to perform essential roles in multiple cancer progression; however, there have been no studies focused on its function and underlying regulatory mechanism in lung cancer.Method: The miR-190 expression was detected by real-time quantitative polymerase chain reaction (RT-qPCR). The cell functional experiments, including cell counting kit-8 (CCK-8), colony formation and transwell assay were conducted in vitro, as well as animal experiments performed in vivo. The regulation and potential binding sites of CBX4 on miR-190 were predicted by TCGA data set and JASPAR website and verified by ChIP assay and dual-luciferase reporter assay. The prospects binding site of miR-190-3p on CBX4 3'UTR region was predicted by StarBase and verified by dual-luciferase reporter assay.Results: MiR-190 was decreased in lung cancer cells. The overexpression of miR-190 had no effects on cell proliferation, but significantly inhibited cancer metastasis both in vitro and in vivo. Moreover, miR-190 expression could be transcriptionally inhibited by CBX4, and CBX4 was the direct target of miR-190-3p.Conclusion: MiR-190 served as a cancer metastasis inhibitor in lung cancer and formed a regulatory loop with CBX4. These findings provided emerging insights into therapeutic targets and strategies for metastatic lung cancer.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141890218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China. 中国食管癌外科治疗近三十年的变化和现状调查。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI: 10.1111/1759-7714.15391

Yong Li, Wei-Xin Liu, Ling Qi, Yin Li, Jun-Feng Liu, Jian-Hua Fu, Yong-Tao Han, Wen-Tao Fang, Zhen-Tao Yu, Ke-Neng Chen, You-Sheng Mao

{"title":"Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China.","authors":"Yong Li, Wei-Xin Liu, Ling Qi, Yin Li, Jun-Feng Liu, Jian-Hua Fu, Yong-Tao Han, Wen-Tao Fang, Zhen-Tao Yu, Ke-Neng Chen, You-Sheng Mao","doi":"10.1111/1759-7714.15391","DOIUrl":"10.1111/1759-7714.15391","url":null,"abstract":"Background: To review the changes and survey on status quo of the surgical treatment for esophageal cancer in China. The differences in diagnosis and treatment for esophageal cancer among hospitals in different regions across China were also investigated.Methods: We sent questionnaires to 46 hospitals across China, investigating the volume of esophageal cancer surgeries, surgical procedures, and perioperative management under the guidance of esophageal surgery chiefs.Results: A total of 46 questionnaires were sent out and collected. The survey results showed that in the past 5 years, the volume of surgeries for esophageal cancer remained stable by 23.9% of those hospitals, increased by 30.4%, and decreased by 45.7%. Of those patients treated by surgery, 19.1% were in the early stages, and 80.9% were in locally advanced stages. In terms of surgical procedures, 73.4% of the patients were treated by minimally invasive surgery and 85.7% of esophageal substitutes were a gastric conduit, 93.1% of the substitutes were pulled to the neck through the esophageal bed. For the lymph node dissection, 78.5% of the patients had a complete two-field lymph node dissection including the para-recurrent laryngeal nerve lymph nodes. Of the patients with neoadjuvant therapy, 53.5% received chemotherapy or chemotherapy plus immunotherapy (47.0%), and 43.5% had chemoradiation.Conclusions: Currently, in China, minimally invasive surgery-oriented multimodality treatment, including complete two-field lymph node dissection, has become the standard approach for esophageal cancer management. Over the past decade, this standardized approach has significantly improved prognosis compared to previous decades.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenge of concomitant thymoma resection and myocardial revascularization: A Case Report. 同时进行胸腺瘤切除术和心肌血管重建术的挑战：病例报告

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-24 DOI: 10.1111/1759-7714.15245

Beatrice Leonardi, Giovanni Natale, Giuseppe Vicario, Mario Grande, Alfonso Fiorelli, Luigi Di Tommaso, Vincenzo Speranza, Daniele Torella, Marisa De Feo, Michele Torella

引用次数: 0

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report. BRAF 和 MEK 抑制剂新辅助治疗可使携带 BRAF V600E 突变的 IIIA 期非小细胞肺癌患者获得病理完全应答：病例报告。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1111/1759-7714.15409

Zhicheng Huang, Yadong Wang, Bowen Li, Yuan Xu, Guanghua Huang, Yang Song, Ji Li, Lan Song, Jinhua Wang, Rongxi Wang, Naixin Liang, Shanqing Li

{"title":"Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.","authors":"Zhicheng Huang, Yadong Wang, Bowen Li, Yuan Xu, Guanghua Huang, Yang Song, Ji Li, Lan Song, Jinhua Wang, Rongxi Wang, Naixin Liang, Shanqing Li","doi":"10.1111/1759-7714.15409","DOIUrl":"10.1111/1759-7714.15409","url":null,"abstract":"In recent years, significant improvement has been made in the management of non-small cell lung cancer (NSCLC), primarily driven by advances in targeted therapy and immunotherapy. Research on neoadjuvant targeted therapy has also experienced considerable development, primarily directed towards NSCLC harboring epidermal growth factor receptor or anaplastic lymphoma kinase mutations. Nevertheless, there remains a dearth of studies investigating neoadjuvant targeted therapy in the context of BRAF (V-Raf murine sarcoma viral oncogene homolog B) V600E mutant NSCLC. Herein, we describe the clinical trajectory of a stage IIIA NSCLC patient who underwent a two-month course of neoadjuvant targeted therapy comprising BRAF and MEK (mitogen-activated extracellular signal-regulated kinase) inhibitors prior to surgical intervention, and subsequent postoperative evaluation unveiled a pathological complete response. The case reported here indicates the efficacy and safety of combining BRAF and MEK inhibitors as neoadjuvant targeted therapy in BRAF V600E-mutant NSCLC and suggests the potential viability of such a therapeutic modality in improving treatment outcomes in this subset of NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TNNT1 accelerates migration, invasion and EMT progression in lung cancer cells. TNNT1 可加速肺癌细胞的迁移、侵袭和 EMT 进展。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-07 DOI: 10.1111/1759-7714.15400

Xiaobin Ge, Guangzhong Du, Qingchen Zhou, Bing Yan, Gonglei Yue

{"title":"TNNT1 accelerates migration, invasion and EMT progression in lung cancer cells.","authors":"Xiaobin Ge, Guangzhong Du, Qingchen Zhou, Bing Yan, Gonglei Yue","doi":"10.1111/1759-7714.15400","DOIUrl":"10.1111/1759-7714.15400","url":null,"abstract":"Background: Clinically, most patients with lung cancer (LC) die from tumor spread and metastasis. Specific metastasis-related molecules can provide reference for clinical prediction of efficacy, evaluation of prognosis, and search for the best treatment plan. Troponin T1 (TNNT1) is highly expressed in various cancer tissues, which affects malignant behavior of tumor cells and is related to patients' survival and prognosis. However, the role and molecular mechanism of TNNT1 in LC invasion and metastasis have not yet been investigated.Methods: Gene expression profiling interactive analysis (GEPIA) online analysis was used to analyze TNNT1 expression in LC tissues. Quantitative real-time-polymerase chain reaction (qRT-PCR) or western blot were performed to measure TNNT1 or epithelial-to-mesenchymal transition (EMT)-related and Wnt/β-catenin pathway-related protein expression in LC cells. After TNNT1 knockdown, cell scratch healing and transwell assays were introduced to assess cell migration and invasion, respectively.Results: TNNT1 expression in LC tissues and cells was increased. TNNT1 knockdown notably impaired LC cell migration, invasion and EMT. TNNT1 knockdown inhibited Wnt/β-catenin pathway of LC cells. Lithium chloride (LiCl) addition partially restored the inhibition of TNNT1 knockdown on migration, invasion, EMT and Wnt/β-catenin of LC cells.Conclusion: TNNT1 knockdown attenuated LC migration, invasion and EMT, possibly through Wnt/β-catenin signaling.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report. 肺鳞癌在初次治疗六年后对尼伐单抗再治疗产生反应：病例报告。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1111/1759-7714.15267

Kento Kono, Kazuhisa Nakashima, Yukari Tsubata, Yoshihiro Amano, Keita Kawakado, Takashi Yanagawa, Takeshi Isobe

{"title":"Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report.","authors":"Kento Kono, Kazuhisa Nakashima, Yukari Tsubata, Yoshihiro Amano, Keita Kawakado, Takashi Yanagawa, Takeshi Isobe","doi":"10.1111/1759-7714.15267","DOIUrl":"10.1111/1759-7714.15267","url":null,"abstract":"A 61-year-old man presented to our hospital with a chief complaint of chronic cough. He was diagnosed with lung squamous cell carcinoma at clinical stage cT2aN3M1a. He received chemotherapy up to the fourth line, but both the primary tumor and lymph node metastases increased in size. Nivolumab, administered as the fifth line, resulted in a complete response (CR) that continued for 2 years and 8 months. Treatment was stopped due to the appearance of common terminology criteria for adverse events grade 1 pneumonitis. He was followed up without treatment for 3 years and 8 months, but a left supraclavicular fossa lymph node metastasis appeared. Retreatment with nivolumab was initiated, and the patient achieved CR again. One year and 6 months after retreatment, CR was maintained with nivolumab. This case represents a rare instance in which nivolumab yielded a significant response after a prolonged immune checkpoint inhibitor (ICI)-free interval. Our experience has shown that the long-term response to ICIs may deteriorate in the future. Therefore, retreatment with ICIs may be effective when the initial therapy is successful.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. 接受免疫检查点抑制剂治疗的非小细胞肺癌患者的营养和炎症生物标志物与总生存期的关系。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI: 10.1111/1759-7714.15401

I M Horstman, P C Vinke, E Suazo-Zepeda, T J N Hiltermann, M A Heuvelmans, E Corpeleijn, G H de Bock

{"title":"The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.","authors":"I M Horstman, P C Vinke, E Suazo-Zepeda, T J N Hiltermann, M A Heuvelmans, E Corpeleijn, G H de Bock","doi":"10.1111/1759-7714.15401","DOIUrl":"10.1111/1759-7714.15401","url":null,"abstract":"Objectives: Pretreatment biomarkers are needed to identify patients with non-small-cell lung cancer (NSCLC) likely to have worse survival. This ensures that only patients with a real chance of benefit receive immune checkpoint inhibitor (ICI) treatment. In this study, we examined the associations of baseline nutritional and inflammatory biomarkers with overall survival in a real-world cohort of NSCLC patients who received ICIs.Materials and methods: We used prospectively collected data from the OncoLifeS data biobank. The cohort included 500 advanced-stage NSCLC patients treated with ICIs from May 2015 to June 2021. Biomarkers were evaluated within 2 weeks before ICI treatment: neutrophil-to-lymphocyte ratio, C-reactive protein (CRP), Glasgow prognostic score, CRP/albumin ratio (CAR), prognostic nutritional index (PNI), and advanced lung cancer inflammation index. For each biomarker, low- and high-risk groups were defined using literature-based cut-offs. Adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were estimated using adjusted survival analysis.Results: Most patients were male (60.8%), the mean baseline age was 65 ± 9 years, and 88% had stage IV disease. For each biomarker, low-risk patients had better overall survival (all, p < 0.001), with CAR and PNI showing the strongest associations. In multivariable analyses a combined CAR/PNI risk score had a stronger association with overall survival (aHR 3.09, 95% CI 2.36-4.06) than CAR alone (aHR 2.22, 95% CI 1.79-2.76) or PNI alone (aHR 2.09, 95% CI 1.66-2.61).Conclusion: These results highlight the potential value of nutritional and inflammatory biomarkers, in particular CAR and PNI, in identifying NSCLC patients with highest mortality risk before starting ICI treatment.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0